Health solution company Quanterix Corporation (NASDAQ:QTRX) said on Monday that the Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) label for its Simoa SARS-CoV-2 N Protein Antigen Test to include testing with nasal swab and saliva samples as well as asymptomatic serial testing with nasal swab samples.
The expanded label establishes the company's Simoa SARS-CoV-2 N Protein Antigen Test as the first antigen test authorized for use with saliva samples. The test is validated to detect all Variants of Concern and is the first non-NGS test validated and independently confirmed to detect the highly transmissible Delta variant (B.1.617.2) in sequence-confirmed clinical samples.
According to the company, the test can be run on its Simoa HD-X Analyzer, a fully automated high-throughput immunoassay instrument. The Simoa SARS-CoV-2 N Protein Antigen Test detects the presence of the SARS-CoV-2 virus nucleocapsid protein (or N protein), which is known to be elevated in respiratory fluids during the initial acute phase of the infection.
In conjunction, the expanded US FDA authorization of the company's Simoa SARS-CoV-2 N Protein Antigen Test is an important next step in a project funded by the NIH Rapid Acceleration of Diagnostics (RADx) initiative to apply Simoa digital biomarker technology to decentralized SARS-CoV-2 antigen detection in non-invasive sample types to increase the capacity of SARS-CoV-2 testing in the US.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT